168 related articles for article (PubMed ID: 6474162)
1. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients.
Pickar D; Labarca R; Linnoila M; Roy A; Hommer D; Everett D; Paul SM
Science; 1984 Aug; 225(4665):954-7. PubMed ID: 6474162
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.
Pickar D; Labarca R; Doran AR; Wolkowitz OM; Roy A; Breier A; Linnoila M; Paul SM
Arch Gen Psychiatry; 1986 Jul; 43(7):669-76. PubMed ID: 3718170
[TBL] [Abstract][Full Text] [Related]
3. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
[TBL] [Abstract][Full Text] [Related]
4. Circadian variation of plasma homovanillic acid levels is attenuated by fluphenazine in patients with schizophrenia.
Doran AR; Labarca R; Wolkowitz OM; Roy A; Douillet P; Pickar D
Arch Gen Psychiatry; 1990 Jun; 47(6):558-63. PubMed ID: 2350208
[TBL] [Abstract][Full Text] [Related]
5. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
[TBL] [Abstract][Full Text] [Related]
6. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
[TBL] [Abstract][Full Text] [Related]
7. Persistence of cyclicity of the plasma dopamine metabolite, homovanillic acid, in neuroleptic treated schizophrenic patients.
Davila R; Zumarraga M; Andia I; Friedhoff AJ
Life Sci; 1989; 44(16):1117-21. PubMed ID: 2565009
[TBL] [Abstract][Full Text] [Related]
8. The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients.
Konicki PE; Owen RR; Litman RE; Pickar D
Life Sci; 1991; 48(14):1411-6. PubMed ID: 2008157
[TBL] [Abstract][Full Text] [Related]
9. Neuroleptics, dopamine, and schizophrenia.
Pickar D
Psychiatr Clin North Am; 1986 Mar; 9(1):35-48. PubMed ID: 2870480
[TBL] [Abstract][Full Text] [Related]
10. Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms.
Khan RS; Amin F; Powchik P; Knott P; Goldstein M; Apter S; Kerman B; Jaff S; Davidson M
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):879-84. PubMed ID: 1980541
[TBL] [Abstract][Full Text] [Related]
11. Plasma homovanillic acid in schizophrenics: supportive evidence for the two-subtype hypothesis.
Chen TY; Lee CF; Lung FW; Lee TC; Lin WL; Hu WH; Yeh EK; Chang WH
Taiwan Yi Xue Hui Za Zhi; 1989 Jun; 88(6):584-8. PubMed ID: 2571672
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients.
Suzuki E; Kanba S; Nibuya M; Adachi S; Sekiya U; Shintani F; Kinoshita N; Yagi G; Asai M
Biol Psychiatry; 1994 Nov; 36(10):654-61. PubMed ID: 7880934
[TBL] [Abstract][Full Text] [Related]
13. Dopamine and schizophrenia.
Crow TJ; Johnstone EC; Deakin JF; Longden A
Lancet; 1976 Sep; 2(7985):563-6. PubMed ID: 60635
[TBL] [Abstract][Full Text] [Related]
14. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results.
Wolkowitz OM; Breier A; Doran A; Kelsoe J; Lucas P; Paul SM; Pickar D
Arch Gen Psychiatry; 1988 Jul; 45(7):664-71. PubMed ID: 3289524
[TBL] [Abstract][Full Text] [Related]
15. A central 6-hydroxydopamine lesion prevents fluphenazine-induced increase in plasma homovanillic acid.
Labarca R; Thomas JW; Koulu M; Kim YS; Janowsky A; Wilkinson L; Linnoila M; Paul SM; Pickar D
Brain Res Bull; 1988 May; 20(5):567-71. PubMed ID: 3133084
[TBL] [Abstract][Full Text] [Related]
16. Plasma homovanillic acid as a predictor of response to neuroleptics.
Davila R; Manero E; Zumarraga M; Andia I; Schweitzer JW; Friedhoff AJ
Arch Gen Psychiatry; 1988 Jun; 45(6):564-7. PubMed ID: 3377643
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on a time-dependent model of neuroleptic action.
Pickar D
Schizophr Bull; 1988; 14(2):255-68. PubMed ID: 2904694
[TBL] [Abstract][Full Text] [Related]
18. Plasma homovanillic acid and tardive dyskinesia during neuroleptic maintenance and withdrawal.
Kirch D; Hattox S; Bell J; Murphy R; Freedman R
Psychiatry Res; 1983 Jul; 9(3):217-23. PubMed ID: 6137850
[TBL] [Abstract][Full Text] [Related]
19. Biochemical alterations produced by neuroleptics in man: studies of plasma homovanillic acid in schizophrenic patients.
Pickar D; Wolkowitz OM; Labarca R; Doran AR; Breier A; Paul SM
Psychopharmacol Ser; 1987; 3():248-54. PubMed ID: 3823092
[No Abstract] [Full Text] [Related]
20. Low-dose apomorphine reduces serum homovanillic acid concentrations in schizophrenic patients.
Cutler NR; Jeste DV; Karoum F; Wyatt RJ
Life Sci; 1982 Mar; 30(9):753-6. PubMed ID: 7070229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
